The Supreme Court is poised to decide whether mailing mifepristone can continue nationwide, after rulings flipped access within days.
A potential new nationwide setback for medication abortion is looming as the Supreme Court considers whether to remove access to mifepristone, a key drug in the most common type of medication abortion.
American patients and clinicians have faced rapid changes in access in recent days. with the court system revoking and then restoring the ability to obtain mifepristone through the mail.. The latest development comes after the Fifth Circuit issued a ruling that prohibited abortion providers from mailing the drug to patients anywhere in the country.
On the Monday that followed the lower-court decision, the Supreme Court temporarily reinstated access to mifepristone at the request of two manufacturers of the medication, Danco Labs and GenBioPro. That temporary order is set to expire next Monday unless the justices act beforehand.
If the Supreme Court allows the underlying prohibition to stand. people across the United States would again be unable to receive mifepristone through the postal system.. Medication abortion. which uses mifepristone as the first step in a two-part regimen. is the most widely used approach in the country. accounting for close to two-thirds of abortions each year.
The legal fight centers on a decision made during the Biden-era by the Food and Drug Administration to end an older requirement that mifepristone be dispensed in person.. Lawyers for Louisiana argue the Biden FDA’s move was intended to undermine the Supreme Court’s 2022 Dobbs decision. which ended constitutional recognition of a right to abortion that had been established in Roe v.. Wade.
The stakes are amplified by the fact that the FDA is now undergoing a formal safety review of mifepristone under new leadership appointed by President Donald Trump.. The dispute includes claims about both safety and efficacy. with the record describing extensive study of the drug over decades and reporting that mifepristone has been shown to be effective in more than 97% of cases. while serious complications are described as arising in less than .025% of cases.
One of the manufacturers’ advocates warned that the case could become a major blow to evidence-based care if the Supreme Court sides with Louisiana.. Skye Perryman. long-time counsel for GenBioPro and CEO and president of the legal advocacy group Democracy Forward. argued that a ruling for the state would amount to a nationwide setback for access to mifepristone.
According to the report, the FDA had asked a lower court to pause the case while its review continued.. After the Fifth Circuit ruled against the agency last week. the FDA did not pursue its own submission to the Supreme Court in the subsequent week. a decision that drew criticism from advocates.. Carrie Flaxman. a senior legal advisor at Democracy Forward. said it was concerning that the agency did not file in time. and argued the justices should defer to the ongoing FDA review and vacate what she called an erroneous nationwide injunction.
Louisiana, which had already succeeded in the Fifth Circuit, responded to the manufacturers’ requests to keep access in place. The state argued it has legal grounds to sue, including that the FDA’s mailing policy infringes on Louisiana’s so-called sovereignty.
Flaxman characterized that argument as inconsistent. saying Louisiana was effectively seeking relief broader than its own borders while asserting an injury framed around state authority.. She pointed to the nationwide reach of the Fifth Circuit’s decision. arguing that the state’s approach disregarded how the ruling limited access in other states as well.
Louisiana asked the Supreme Court to keep the Fifth Circuit’s prohibition in effect.. At the same time. if the justices decide not to do so. Louisiana requested that the high court take up the case immediately and schedule oral arguments before the court adjourns for the summer—within the next few weeks.
The Supreme Court has not yet indicated whether it will decide Louisiana’s request or whether it will allow medication abortion to remain accessible across the country while the litigation proceeds.. Providers and patients. meanwhile. are left waiting for a ruling that could reshape what access looks like in the days immediately ahead.
The unusual sequence of rulings—moving from restriction to emergency restoration and facing another possible reversal—underscores how quickly federal legal decisions can translate into real-world care interruptions.. For many patients. mifepristone is not a remote policy question but a time-sensitive medical option. and the expiration of the Supreme Court’s temporary order may force another abrupt shift in access nationwide.
MISRYOUM
Supreme Court mifepristone medication abortion FDA Louisiana v. FDA